Angiohematopoietic Progenitor Cells

Abstract

A purified human cell population of subsets of angiohematopoietic progenitor cells, wherein the population is at least 94% pure and wherein the cells are selected with cell markers selected from the group of KDR, APLNR, VE-cadherin, PDGFRα, CD31, CD235a, CD73, CD43, and CD41a.

1 . A purified human cell population of hematovascular mesodermal precursors (Cell Population A), wherein the population is at least 94% pure and wherein the cells are characterized as VE-cadherin − , KDR bright , APLNR + , PDGFRα low− . 
     
     
         2 . The cell population of  claim 1 , wherein the population expresses the gene for TRPA1 mechano- and chemoreceptor. 
     
     
         3 . The cell population of  claim 1 , wherein the cells are capable of forming hematoendothelial colonies with at least 1 in 10 frequency. 
     
     
         4 . A purified human cell population of hemogenic endothelial progenitors (Cell Population D, VE-cadherin+,CD73−CD235a/CD43−); angiogenic hematopoietic progenitors (Cell Population E, VE-cadherin+CD235a/CD43+CD41a−) or non-hemogenic endothelial progenitors (Cell Population C, VE-cadherin+CD73+) wherein the cell population is at least 94% pure. 
     
     
         5 . The hemogenic endothelial cells of  claim 4 , wherein the cells are CD117 intermediate . 
     
     
         6 . The angiogenic hematopoietic progenitor cells of  claim 4 , wherein the cells are CD73−. 
     
     
         7 . The non-hemogenic endothelial progenitors cells of  claim 4  wherein the cells are CD117 high  and CD73+. 
     
     
         8 . A method of examining a drug for ability to modify cell differentiation, comprising the step of exposing at least one of the cell populations of  claim 1  to a test drug and observing the effect of the drug on cell growth, differentiation, or viability. 
     
     
         9 . A method of examining a drug for ability to modify cell differentiation, comprising the step of exposing at least one of the cell populations of  claim 4  to a test drug and observing the effect of the drug on cell growth, differentiation, or viability. 
     
     
         10 . A method of obtaining the cell populations of  claim 1  comprising the steps of:
 a) culturing pluripotent stem cells so that hematoendothelial differentiation occurs, and 
 b) sorting the cells by cell markers selected from the group consisting of KDR, APLNR, VE-cadherin, PDGFRα, CD31, CD235a, CD73, CD43, and CD41a such that a purified cell population of the cells of  claim 1  is obtained. 
 
     
     
         11 . A method of obtaining the cell populations of  claim 4  comprising the steps of:
 a) culturing pluripotent stem cells so that hematoendothelial differentiation occurs, and 
 b) sorting the cells by cell markers selected from the group consisting of VE-cadherin, CD235a, CD73, CD43, and CD41a such that a purified cell population of at least one of the cell populations of  claim 4  is obtained. 
 
     
     
         12 . A method of treating a patient, comprising the step of supplying at least one of the cell populations of  claim 1  in a therapy selected from the group of bone marrow transplantation, blood transfusion, immunotherapy, treatment of cardiovascular diseases, treatment of ischemia, diabetic ulcers, regeneration of vasculature, and artificial tissue constructs. 
     
     
         13 . A method of treating a patient, comprising the step of supplying at least one of the cell populations of  claim 4  in a therapy selected from the group of bone marrow transplantation, blood transfusion, immunotherapy, treatment of cardiovascular diseases, treatment of ischemia, diabetic ulcers, regeneration of vasculature, and artificial tissue constructs. 
     
     
         14 . A method of treating a patient in need of blood cell reconstitution and/or restoration of endothelial cell activity comprising the step of administering the cell population of  claim 1  to a patient, wherein the cells will differentiate into blood cells or endothelial cells. 
     
     
         15 . A method of treating a patient in need of blood cell reconstitution and/or restoration of endothelial cell activity comprising the step of administering at least one of the cell populations of  claim 4  to a patient, wherein the cells will differentiate into blood cells or endothelial cells.